Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients
- PMID: 24256562
- DOI: 10.1111/cen.12370
Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients
Abstract
Context: Prolactinoma is the most frequent pituitary tumour among women of child-bearing age. Only a few studies have addressed the outcome of prolactinoma after pregnancy.
Objective: To study remission, defined as prolactin normalization without medical treatment, after pregnancy and lactation in women with prolactinoma.
Patients and methods: A retrospective study conducted in 2 Belgian academic centres including 73 patients (54 microprolactinomas and 19 macroprolactinomas) with 104 pregnancies continuing beyond first trimester. Dopamine agonists were stopped in early pregnancy in all treated cases. Prolactin level and adenoma size at pituitary magnetic resonance imaging (MRI) were recorded before pregnancy and throughout follow-up.
Results: Thirty of 73 women (41%) were in remission after a median follow-up of 22 months after delivery or cessation of lactation. Adenoma size at diagnosis was smaller in women in remission (5 vs 8 mm). There was a nonsignificant higher rate of remission for microprolactinomas than for macroprolactinoma (46% vs 26%). The first pituitary MRI after pregnancy and lactation showed no tumour and a decreased adenoma size in 23% and 39% of women, respectively. MRI normalization was associated with remission. The number of pregnancies per woman as well as breastfeeding and its duration did not influence remission rate.
Conclusion: More than 40% of women with previous diagnosis of prolactinoma have normal PRL level without medical treatment for a median follow-up of 22 months after pregnancy and lactation. The likelihood of remission is associated with a smaller initial adenoma size and normalization of pituitary MRI after pregnancy.
© 2013 John Wiley & Sons Ltd.
Similar articles
-
An observational study of pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists.Aust N Z J Obstet Gynaecol. 2020 Jun;60(3):405-411. doi: 10.1111/ajo.13070. Epub 2019 Oct 3. Aust N Z J Obstet Gynaecol. 2020. PMID: 31583693
-
Primary medical therapy of micro- and macroprolactinomas in men.J Clin Endocrinol Metab. 2000 Sep;85(9):3053-7. doi: 10.1210/jcem.85.9.6798. J Clin Endocrinol Metab. 2000. PMID: 10999785 Clinical Trial.
-
Prolactinoma and pregnancy: From the wish of conception to lactation.Ann Endocrinol (Paris). 2016 Jun;77(2):128-34. doi: 10.1016/j.ando.2016.04.001. Epub 2016 Apr 26. Ann Endocrinol (Paris). 2016. PMID: 27130071 Review.
-
Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.Eur J Endocrinol. 2012 May;166(5):779-86. doi: 10.1530/EJE-11-1000. Epub 2012 Feb 2. Eur J Endocrinol. 2012. PMID: 22301915
-
[Effects of therapy and pregnancy on hyperprolactemia caused by a pituitary adenoma. A clinical case].Minerva Ginecol. 1989 Mar;41(3):157-60. Minerva Ginecol. 1989. PMID: 2666885 Review. Italian.
Cited by
-
Clinical Biology of the Pituitary Adenoma.Endocr Rev. 2022 Nov 25;43(6):1003-1037. doi: 10.1210/endrev/bnac010. Endocr Rev. 2022. PMID: 35395078 Free PMC article. Review.
-
Hyperprolactinaemia.J Clin Med. 2019 Dec 13;8(12):2203. doi: 10.3390/jcm8122203. J Clin Med. 2019. PMID: 31847209 Free PMC article. Review.
-
Controversies in Breastfeeding.Front Pediatr. 2018 Nov 1;6:278. doi: 10.3389/fped.2018.00278. eCollection 2018. Front Pediatr. 2018. PMID: 30443539 Free PMC article. Review.
-
Pituitary disorders in pregnancy.Clin Med (Lond). 2025 Jul 29;25(5):100488. doi: 10.1016/j.clinme.2025.100488. Online ahead of print. Clin Med (Lond). 2025. PMID: 40744144 Free PMC article. Review.
-
Dopamine agonists in prolactinomas: when to withdraw?Pituitary. 2020 Feb;23(1):38-44. doi: 10.1007/s11102-019-00989-1. Pituitary. 2020. PMID: 31556013 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical